Perception Neuroscience
1 known investors
Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression. The company licenses intellectual property originally discovered at Chiba University and is running a Phase 2a proof-of-concept clinical trial.
Investors · 1
Frequently asked questions
- What does Perception Neuroscience do?
- Perception Neuroscience is a clinical-stage biotech developing R-ketamine (PCN-101), a single-isomer glutamatergic modulator being studied as a rapid-acting antidepressant for patients with treatment-resistant depression. The company licenses intellectual property originally discovered at Chiba University and is running a Phase 2a proof-of-concept clinical trial.
- Who are Perception Neuroscience's investors?
- Perception Neuroscience's investors include Sofinnova Ventures.